WAYNE, Pa.--(BUSINESS WIRE)--Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced the U.S. Food and Drug Administration has granted conditional approval for a U.S. and European IDE clinical trial to investigate use of the Tack Endovascular System as a dissection repair therapy in patients with peripheral arterial disease (P.A.D.) undergoing percutaneous angioplasty. The Tack Optimized Balloon Angioplasty II (TOBA II) trial has begun with the first patients being treated at Yuma Regional Medical Center (Yuma, Arizona).
Help employers find you! Check out all the jobs and post your resume.
